Reasons for breakthrough CMV disease in patients who receive preemptive therapy

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2858-

  Limaye, A P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS INFECTION; HUMAN; KIDNEY GRAFT; LETTER; LIVER GRAFT; PREEMPTIVE THERAPY; PRIORITY JOURNAL; THERAPY; VIREMIA;

COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; HUMANS;

EID: 84867044192     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04229.x     Document Type: Letter

References (2)

1. Atabani SF, Smith C, Atkinson C, et al,. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457-2464.
2. Paya C, Humar A, Dominguez E, et al,. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.